Navigation Links
Lotus Pharmaceuticals Announces Second Quarter 2008 Results
Date:8/18/2008

the project is an estimated RMB 50 million (approximately $7.1 million).

2008 Outlook

"We recently obtained the patent and exclusive production rights to a new asthma drug, Laevo-Bambutero, which we plan to launch in 2012 after we receive approval from the SFDA. We currently have fourteen drugs for which we are seeking SFDA approval, and plans for manufacturing a number of new pharmaceutical products," said Dr. Liu. "In 2008, we expect strong revenue growth to be led by our distribution of pharmaceutical products manufactured by third-parties and our best selling branded products. For the full year 2008, because of our growing distribution network, we remain confident that we will meet our 'make good' net income target of $13.1 million."

"As part of our longer term growth strategy, we began the process of acquiring land use rights on which to construct a product development and manufacturing facility that will allow us produce a wide range of new pharmaceutical products. We hope to have the facility completed by the end of 2010. However, we may adjust the time line depending on our availability of working capital and external funds. We obtained the land use rights at a favorable price and may be able to monetize a portion of them in the future."

Conference Call

Lotus' management will host a conference call at 10:00 a.m. Eastern Time on Monday, August 18, 2008 to discuss results for the quarter ended June 30, 2008. To participate in this live conference call, please dial the following number five to ten minutes prior to the scheduled conference call time: 888- 481-7939. International callers should call 617-847-8707. The Conference Pass Code is 306 650 22.

Replay of the conference call will be available from 12 p.m. Eastern Time on Monday, August 18 for fourteen days. To access the replay, call 888-286- 8010. International callers should call 617-801-6888. The Conference Pass Code is 939 152 01.

Use of Non-GAAP Financi
'/>"/>

SOURCE Lotus Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... 4, 2015 Lancée ... Paris en décembre 2011, l,étude collaborative ... », qui compare   l es microsphères ... sorafénib dans le carcinome hépatocellulaire avancé, a recruté ... foie avancé   ; les résultats sont attendus ...
(Date:3/3/2015)... 2015 NASA astronaut Scott Kelly , who ... spend a year living and working on the International Space ... to 7 a.m. EDT Monday, March 9. Kelly ... completes the final weeks of his training. The interviews will ... Television highlighting his mission training and previous spaceflights. ...
(Date:3/3/2015)... SAN DIEGO , March 3, 2015  Neurocrine ... that Kevin Gorman , President and Chief Executive ... Barclays Global Healthcare Conference in Miami.   ... at 10:15am ET (7:15am PT).  The presentation will be ... at http://www.neurocrine.com .   Listeners are ...
(Date:3/3/2015)... March 03, 2015 Crown Bioscience, Inc., ... has launched a new Life Science division specializing in ... research. , The first products released include in ... and soon to be released in vivo grade monoclonal ... to expand their life science portfolio with additional antibody ...
Breaking Biology Technology:Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 2Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 3Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 4Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 5Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 6NASA Astronaut Scott Kelly Available for Interviews before One-Year Space Station Mission 2Crown Bioscience Launches Life Science Product Catalog 2
... Basis, Proprietary MicroRNAs for Research Applications ... has Access to a Full Range of ... on These MicroRNAs, REHOVOT, Israel and JERSEY CITY, ... ), a leading,developer of microRNA-based diagnostics and therapeutics, announced ...
... Alfacell Corporation,(Nasdaq: ACEL ) today announced that Kuslima ... retire from the company on,or before March 31, 2009. ... Shogen and Alfacell has been terminated., The termination ... reduce payments from the Company to Ms. Shogen by ...
... to Date Examined 175,000 Teenage Girls and Adult ... before motherhood,more than doubled in six years among ... study published in the May issue of Diabetes ... looked exclusively at gestational diabetes,(diabetes that develops during ...
Cached Biology Technology:Rosetta Genomics Announces Expansion of its MicroRNA Intellectual Property Estate 2Rosetta Genomics Announces Expansion of its MicroRNA Intellectual Property Estate 3Rosetta Genomics Announces Expansion of its MicroRNA Intellectual Property Estate 4Alfacell Announces Retirement of Chief Executive Officer 2Alfacell Announces Retirement of Chief Executive Officer 3Alfacell Announces Retirement of Chief Executive Officer 4Kaiser Permanente Study Finds Diabetes Doubling Before Motherhood 2Kaiser Permanente Study Finds Diabetes Doubling Before Motherhood 3Kaiser Permanente Study Finds Diabetes Doubling Before Motherhood 4
(Date:2/5/2015)... 30, 2015  It is gratifying to see that ... for genomic science as a means to better understand ... treatment.  I was honored to participate in today,s White ... program. Since the 1980s my teams ... the first sequenced genome of a free living organism, ...
(Date:1/22/2015)... CHICAGO , Jan. 9, 2015 Valid S.A. ("Company") ... the market in general the State of Washington,s ... contract for a new enrollment and central issuance system for ... The project planning and development will start ...
(Date:1/22/2015)... Showcase, Hall E -   EyeLock Inc. , a market ... showcase its EyeLock ID technology integrated in a 3D printed ... Oak Ridge National Laboratory (ORNL) at the 2015 ... technology is being used to validate the driver and authorize ...
Breaking Biology News(10 mins):J. Craig Venter, Ph.D., Co-Founder and CEO, Human Longevity, Inc. (HLI) Participates in White House Precision Medicine Event 2Valid USA Signs Contract For Washington Driver's License Issuance 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 3
... SALT LAKE CITY People who are at risk ... cancer may soon have a better chance at surviving or ... by the Intermountain Clinical Genetics Institute at LDS Hospital. ... to develop a reliable and cost-effective way to identify patients ...
... DC -- A team of researchers at the Department ... exact, single gene that controls ethanol production capacity in ... in developing biomass crops that produce higher concentrations of ... of Energy relies on the scientific discoveries of its ...
... of mammary gland biology are essential in the fight ... as an Experimental Model , this organ represents an ... processes that occur throughout the body. The branching morphogenesis ... pregnancy, for example, recapitulate steps that occur in many ...
Cached Biology News:New process that may save lives of cancer patients is effective and significantly less costly 2New process that may save lives of cancer patients is effective and significantly less costly 3Single, key gene discovery could streamline production of biofuels 2
Rabbit polyclonal antibody to NMDA NR2B [Tyr1336]...
... with the DeCypher Engine accelerator cards to speed ... searches like these from your desktop: BLAST ... 6 days Align BAC-sized queries (~250 ... analysis to compare 100,000 sequences to PFAM in ...
... tetrasodium bromide), 50mg/vial. MTT is a pale ... cells to yield a dark blue formazan ... even freshly dead cells do not cleave ... a component of Chemicons MTT assay kit, ...
Mouse monoclonal antibody to FMN2 - formin 2...
Biology Products: